1)Aarsland D, Larsen JP, Lim NG, et al:Range of neuropsychiatric disturbance in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 67:492-496, 1999
2)Baskys A:Lewy body dementia:The litmus test for neuroleptic sensitivity and extrapyramidal symptoms. J Clin Psychiatry 65(Suppl 11):16-22, 2004
3)El-Okdi NS, Lumbrezer D, Karanovic D, et al:Serotonin syndrome after the use of tramadol and ziprasidone in a patient with a deep brain stimulator for Parkinson disease. Am J Ther 21:e97-e99, 2014
4)井貫正彦,遠藤博久,八木下敏志行:幻視に対してtrazodoneが奏功したレビー小体型痴呆の2症例.精神医学 47:725-732, 2005
5)McKeith IG, Boeve BF, Dickson DW, et al:Diagnosis and management of dementia with Lewy bodies. Fourth consensus report of DLB Consortium. Neurology 89:88-100, 2017
6)Michl J, Scharinger C, Zauner M, et al:A multivariate approach linking reported side effects of clinical antidepressant and antipsychotic trials to in vitro binding affinities. Eur Neuropsychopharmacol 24:1463-1474, 2014
7)奥平智之,安藝竜彦,青木浩義,他:仮性うつ病を呈しSSRIの投与により幻視が増悪したレビー小体型認知症の1例:仮性うつ病を呈したレビー小体型認知症.老年精神医学雑誌 20(増2):132, 2009
8)Okun MS, Watts RL:Depression associated with Parkinson's disease:Neurology 58(Suppl 1):S63-S70, 2002
9)パーキンソン病治療ガイドライン作成委員会,日本神経学会監修:パーキンソン病治療ガイドライン2011.医学書院,2011
配合錠添付文書.日本標準商品分類番号871149.2011年7月薬価収載